Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGynecological OncologyradiotherapyDiseaseCervical CancerSubgroupICD10C53.-MeSHUterine Cervical NeoplasmsSequenceBEVA15/PACL175/CRBP5, Cervical Ca (PID2605) -|- BEVA15, maint. (PID2611)KEYNOTE-826: PEMB200/PACL175/CISP50, Cervical Ca, C1-6 (PID1900) -|- PEMB200, C7+ (PID1893)KEYNOTE-826: PEMB200/PACL175/CISP50/BEVA15, Cervical Ca, C1-6 (PID1891) -|- PEMB200/BEVA15, C7+ (PID2251) or PEMB200, C7+ (PID1893).KEYNOTE-826: PEMB200/PACL175/CRBP5, Cervical Ca, C1-6 (PID1892) -|- PEMB200, C7+ (PID1893)KEYNOTE-826: PEMB200/PACL175/CRBP5/BEVA15, Cervical Ca, C1-6 (PID1890) -|- PEMB200/BEVA15, C7+ (PID2251) or PEMB200, C7+ (PID1893).PACL135/CISP30/Radiation, Cervical Ca (PID1990)ChemotherapyChemo-substanceBevacizumabCarboplatinCemiplimabCisplatinPaclitaxelPembrolizumabTisotumab vedotinTopotecanChemo-substanceBevacizumabCarboplatinCemiplimabCisplatinPaclitaxelPembrolizumabTisotumab vedotinTopotecanChemo-substanceBevacizumabCarboplatinCemiplimabCisplatinPaclitaxelPembrolizumabTisotumab vedotinTopotecanChemo-substanceBevacizumabCarboplatinCemiplimabCisplatinPaclitaxelPembrolizumabTisotumab vedotinTopotecanNo. Substances1234 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%NaphazolinePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%NaphazolinePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%NaphazolinePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%NaphazolinePegfilgrastimPotassium chlorideNo. Substances13456789Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseMaintenanceTherapy intentioncurativepalliativeRisksAbdominal PainAdrenal InsufficiencyAllergic ReactionAlopeciaAnemia Hb below 8g/dlAnorexiaArthalgiaAstheniaBleedingCardiotoxicityConjunctivitisConstipationDiarrheaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaFistulasGastrointestinal ToxicityHand-Foot SyndromeHemorrhageHepatotoxicityHyperglycemiaHypertensionHyperthyroidismHypokalemiaHypophysitisHypothyroidismIncrease AminotransferasesInfectionsLeukopeniaMyalgiasNeuropathyNeutropeniaOral MucositisPainPneumonitisPruritusPyrexiaRashRenal FailureThrombocytopenia below 50 000/µlThromboembolic EventVisual DisturbancesVomiting only studiesPublicationAuthorChung HCColombo NHong DSHuang HKatanyoo KKitagawa RLong HSehouli JTewari KSDiseasefortgeschrittenes oder rezidiviertes Zervixkarzinom, Stadium IVb, ECOG 0-2fortgeschrittenes Zervix-Ca, nach Vorbehandlung, ECOG 0-1fortgeschrittenes Zervixkarzinom, Stadium IIb-IVaLokal fortgeschrittenes oder metastasierten Zervixkarzinom, ohne Möglichkeit einer kurativen Therapie, Erstlinie, ECOG 0-1Metastasierendes, wiederkehrendes oder persistierendes Zervix Ca, ECOG/GOG 0-1metastasiertes, wiederkehrendes oder persistierendes Zervix Ca, ECOG/GOG 0-1metastasiertes oder wiederkehrendes Zervixkarzinom, Platin-Vortherapie, keine Taxan-Vortherapie, ECOG 0-2Zervix-Ca, metastasiert oder rezidiviert, Progress nach platinhaltiger Therapie, ECOG 0-1Zervix-Ca lokal fortgeschritten, nicht operabel oder metastasiert, nach platinhaltiger Therapie, ECOG 0-1Zervix Ca, FIGO IB1, IB2, IIA1, IIA2, nach Hysterektomie und pelviner LymphadenektomieZervixkarzinom, FIGO Stadium IB2-IIB oder IBI + Risikofaktoren, nach radikaler HysterektomieZervixkarzinom, rezidiviert oder metastasiert, ECOG 0-1OriginCollaborative Innovation Center for Cancer Medicine, Guangzhou, China, STARS trialDepartment of Radiology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, ThailandMayo Clinic College of Medicine, Rochester, MN, GOG StudyNOGGO-AGONRG Oncology-Gynecologic Oncology Group (GOG240)NTT Medical Center Tokyo, Trial JCOG0505The University of Texas MD Anderson Cancer Center, Texas, USA, innovaTV 201 studyUniversity of California, Irvine, CA, EMPOWER- Cervical 1/GOG-3016/ENGOT-cx9University of Milan-Bicocca, European Institute of Oncology IRCCS, Italy, KEYNOTE-826 trialUniversity of Milan–Bicocca and European Institute of Oncology IRCCS, MilanYonsei Cancer Center, Yonsei University College of Medicine, Seoul, KEYNOTE 158Protocols in Revision 19 protocols foundProtocols under revision.Bevacizumab 15 / Paclitaxel 175 / Carboplatin 5, Cervical Cancer (PID2605)Bevacizumab 15, Cervical Cancer, maintenance (PID2611)Carboplatin 2 / Radiation, Cervical Cancer (PID1939)Cemiplimab 350, Cervical Cancer (PID1981)Cisplatin 40 / Radiation, Cervical Cancer Adjuvant (PID540)Paclitaxel 135 / Cisplatin 30 / Radiation, Cervical Carcinoma (PID1990)Paclitaxel 175 / Carboplatin 5 followed by Radiation, Cervical Cancer adjuvant (PID97)Paclitaxel 175 / Carboplatin 5, Cervical Cancer (PID1937)Paclitaxel 175 / Cisplatin 50 / Bevacizumab 15, Cervical Cancer (PID600)Paclitaxel 175 / Topotecan 0.75 / Bevacizumab 15, Cervical Cancer (PID769)Pembrolizumab 200 / Bevacizumab 15, Cervical Cancer, Cycle 7+ (PID2251)Pembrolizumab 200 / Paclitaxel 175 / Carboplatin 5 / Bevacizumab 15, Cervical Cancer, Cycle 1-6 (PID1890)Pembrolizumab 200 / Paclitaxel 175 / Carboplatin 5, Cervical Cancer, Cycle 1-6 (PID1892)Pembrolizumab 200 / Paclitaxel 175 / Cisplatin 50 / Bevacizumab 15, Cervical Cancer, Cycle 1-6 (PID1891)Pembrolizumab 200 / Paclitaxel 175 / Cisplatin 50, Cervical Cancer, cycle 1-6 (PID1900)Pembrolizumab 200, Cervical Cancer (PID1331)Pembrolizumab 200, Cervical Cancer, Cycle 7+ (PID1893)Tisotumab Vedotin 2, Cervical Carcinoma (PID2002)Topotecan 0.75 / Cisplatin 50, Cervical Cancer (PID1938)